(Circulation. 1999;100:789-792.)
© 1999 American Heart Association, Inc.
Brief Rapid Communication |
From Thoraxcenter (M.A.C., M.S., W.J.v.d.G., I.P.K., P.C., J.M.R.L., P.S., P.W.S.), Dijkzigt University Hospital, and Daniel den Hoek Cancer Center (V.L.M.A.C., P.C.L.), Rotterdam, The Netherlands.
Correspondence to Prof Patrick W. Serruys, Head of the Department of Interventional Cardiology, University Hospital Dijkzigt-Thoraxcenter Bd418, Dr. Molewaterplein,403015GD Rotterdam, The Netherlands. E-mail serruys{at}card.azr.nl
| Abstract |
|---|
|
|
|---|
Methods and ResultsFrom April 1997 to March 1999, we successfully treated 108 patients with PTCA followed by intracoronary ß-radiation. Ninety-one patients have completed at least 2 months of clinical follow-up. Of these patients, 6.6% (6 patients) presented with sudden thrombotic events confirmed by angiography 2 to 15 months after intervention (2 balloon angioplasty and 4 stent). Some factors (overlapping stents, unhealed dissection) may have triggered the thrombosis process, but the timing of the event is extremely unusual. Therefore, the effect of radiation on delaying the healing process and maintaining a thrombogenic coronary surface is proposed as the most plausible mechanism to explain such late events.
ConclusionsLate and sudden thrombosis after PTCA followed by intracoronary radiotherapy is a new phenomenon in interventional cardiology.
Key Words: thrombosis angioplasty radioisotopes
| Introduction |
|---|
|
|
|---|
Intracoronary radiation is a promising new therapy to prevent restenosis. Recent randomized trials demonstrated a reduction in the restenosis rate and maintenance of benefits up to 2-year follow-up.4 5 6 Presently, limited data are available regarding long-term safety after intracoronary brachytherapy.5 7 Although subacute thrombosis has been reported after radiotherapy,4 8 9 the incidence of late thrombotic events has not been determined.
The aim of this study was to document the incidence of late (>1 month) thrombotic events after elective PTCA followed by intravascular radiotherapy.
| Methods and Results |
|---|
|
|
|---|
All patients were discharged without complications. Ninety-one patients completed at least 2-month clinical follow-up. We observed 1 case of subacute thrombosis occurring 15 days after stenting. This patient received an 18-mm long stent (postdilated at 10 atm) with optimal IVUS result. Ticlopidine withdrawal (12 days after stenting) was the plausible explanation of thrombosis in this case.
Six patients (6.6%) presented with sudden late
thrombotic coronary occlusion. Two of them were treated with BA
and the remaining 4 received an additional stent after radiation. Their
clinical characteristics are summarized in the Table
. No
clinical or anatomic characteristic appeared to be related to these
events.
|
In patient 1, overlapping 9- and 32-mm NIR stents (Medinol Ltd) were optimally implanted as assessed by IVUS. Patients 2 and 3 (BA) showed type B dissections without compromising flow postprocedure. Patients 4 and 5 both received a Multilink 25-mm stent (Advanced Cardiovascular Systems/Guidant), and patient 6 received a NIR 16-mm stent with optimal angiographic results. Stent patients were discharged on aspirin (250 mg/d) and ticlopidine (250 mg BID for 15 days in patients 3 and 4, and for 30 days in cases 5 and 6). BA patients received aspirin alone.
Patient 1 was readmitted with ventricular
fibrillation 2 months after the procedure, whereas, patients 2, 5, and
6 sustained inferior myocardial infarctions (MI) between
2.5 and 3 months after the treatment. The irradiated segment was
occluded at 6-month angiogram in patients 1 and 2 (Figure 1
). Thrombotic occlusion was successfully
treated by primary angioplasty in patients 5 and 6.
|
In patient 3, the 6-month IVUS control revealed a persistent
(unhealed) submedial dissection (Figure 2
) with no signs of restenosis.
Nine months later, this patient sustained a posterolateral MI which was
treated with thrombolytics. Two weeks after this
treatment, an angiogram performed because of recurrent angina showed
the occlusion in the irradiated area. Similarly, the 6-month IVUS
control of patient 4 showed no neointimal hyperplasia. Four
months after control, she had a stroke and aspirin was replaced by
acenocoumarol. Ten days later, she sustained an anterior MI. The
thrombotic occlusion in the treated site was confirmed by
angiography.
|
| Discussion |
|---|
|
|
|---|
Coronary dissection after BA is associated with abrupt closure; however, type B dissections (NHLBI classification), as observed after BA in our patients, have not been related to thrombotic events.13 The normal healing process, present after dissections, may be impaired after intracoronary radiation.14 Whether unhealed dissections, as demonstrated in patient 3, is related to late thrombosis remains to be elucidated in a larger population. Further, the necessity of stenting mild dissections without compromising flow after radiotherapy should be investigated.
The mean time of subacute thrombosis after stenting is approximately 5 to 6 days.2 3 In a recent study, subacute thrombosis occurred within the first 24 hours in 86% of patients treated with aspirin and ticlodipine for 14 days, with no case of thrombotic events occurring after 15 days.15 Colombo et al reported only 2 cases (0.6%) of thrombosis occurring 2 to 6 months after stenting.2 In contrast, in our study, 4 patients receiving a stent (8.8%) experienced thrombosis late after radiation.
Experimentally, reendothelialization after injury takes >4 weeks to be completed.16 However, the clinical presentation of subacute thrombosis infrequently occurs later than 15 days after stenting,15 when the reendothelialization process may still be incomplete. Delayed reendothelialization as a trigger mechanism of late stent thrombosis after antineoplastic therapy has been hypothesized previously.17 Farb et al reported incomplete endothelialization 3 months after placement of ß-radioactive stent.18 Nevertheless, the same group showed no differences regarding endothelial cell growth between radioactive and control stents in another experimental model.19 Further studies should address the timing of stent reendothelialization after brachytherapy to determine its role on the pathogenesis of late thrombosis.
Although multiple stents have been related to subacute thrombosis,20 the significance of multiple stent implantation (patient 1) on late thrombotic phenomena has not been demonstrated.
The use of intracoronary ß-radiation is a common feature in our patients. However, the judgment of whether radiation is the key factor in the pathogenesis of late thrombosis should await the analysis of ongoing trials. Concomitantly, the benefit of prolonged antiplatelet therapy with the combination of aspirin, clopidogrel, or ticlopidine should be considered.
Limitations
Our patients were included in well-controlled ß-radiation
studies with similar baseline characteristics and inclusion criteria
(lesion length <15 mm, treatment of single vessel). However, 2
different systems to deliver ß-radiation were used.
In addition, it is not possible to rule out the natural history of coronary disease as a cause of late thrombosis. However, the incidence of total occlusion in the general nonirradiated population is much lower than that observed in our study. In fact, the incidence of late thrombotic events would be even higher if, in the interest of completeness, we waited for 1-year follow-up in the total patient population.
Finally, whether late thrombosis is a generic complication of intracoronary radiotherapy or is restricted to the use of ß-sources cannot be extrapolated from our findings.
Received May 10, 1999; revision received June 12, 1999; accepted June 24, 1999.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. G. Ellis, C. D. O'Shaughnessy, S. L. Martin, K. Kent, T. McGarry, M. A. Turco, D. J. Kereiakes, J. J. Popma, M. Friedman, J. Koglin, et al. Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial Eur. Heart J., July 1, 2008; 29(13): 1625 - 1634. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Wilson and J. T. Willerson Myocardial Revascularization with Percutaneous Devices Card. Surg. Adult, January 1, 2008; 3(2008): 573 - 598. [Full Text] |
||||
![]() |
M. Awata, J.-i. Kotani, M. Uematsu, T. Morozumi, T. Watanabe, T. Onishi, O. Iida, F. Sera, S. Nanto, M. Hori, et al. Serial Angioscopic Evidence of Incomplete Neointimal Coverage After Sirolimus-Eluting Stent Implantation: Comparison With Bare-Metal Stents Circulation, August 21, 2007; 116(8): 910 - 916. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Cutlip, S. Windecker, R. Mehran, A. Boam, D. J. Cohen, G.-A. van Es, P. Gabriel Steg, M.-a. Morel, L. Mauri, P. Vranckx, et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions Circulation, May 1, 2007; 115(17): 2344 - 2351. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Camenzind, P. G. Steg, and W. Wijns A Cause for Concern Circulation, March 20, 2007; 115(11): 1440 - 1455. [Full Text] [PDF] |
||||
![]() |
P. W. Serruys and J. Daemen Late Stent Thrombosis: A Nuisance in Both Bare Metal and Drug-Eluting Stents Circulation, March 20, 2007; 115(11): 1433 - 1439. [Full Text] [PDF] |
||||
![]() |
M. Pfisterer, H. P. Brunner-La Rocca, P. T. Buser, P. Rickenbacher, P. Hunziker, C. Mueller, R. Jeger, F. Bader, S. Osswald, C. Kaiser, et al. Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents: An Observational Study of Drug-Eluting Versus Bare-Metal Stents J. Am. Coll. Cardiol., November 1, 2006; (2006) j.jacc.2006.10.026v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. W. Stone, J. J. Popma, and S. G. Ellis Paclitaxel-Eluting Stents, Brachytherapy, and In-Stent Restenosis--Reply JAMA, October 18, 2006; 296(15): 1838 - 1839. [Full Text] [PDF] |
||||
![]() |
G. W. Stone, S. G. Ellis, C. D. O'Shaughnessy, S. L. Martin, L. Satler, T. McGarry, M. A. Turco, D. J. Kereiakes, L. Kelley, J. J. Popma, et al. Paclitaxel-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal Stents: The TAXUS V ISR Randomized Trial JAMA, March 15, 2006; 295(11): 1253 - 1263. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Raja Drug-Eluting Stents and the Future of Coronary Artery Bypass Surgery: Facts and Fiction. Ann. Thorac. Surg., March 1, 2006; 81(3): 1162 - 1171. [Abstract] [Full Text] [PDF] |
||||
![]() |
E Iofina, P W Radke, P Skurzewski, P K Haager, R Blindt, K-C Koch, P Hanrath, J vom Dahl, and R Hoffmann Superiority of sirolimus eluting stent compared with intracoronary {beta} radiation for treatment of in-stent restenosis: a matched comparison Heart, December 1, 2005; 91(12): 1584 - 1589. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ako, Y. Morino, Y. Honda, A. Hassan, S. Sonoda, P. G. Yock, M. B. Leon, J. W. Moses, H. N. Bonneau, and P. J. Fitzgerald Late Incomplete Stent Apposition After Sirolimus-Eluting Stent Implantation: A Serial Intravascular Ultrasound Analysis J. Am. Coll. Cardiol., September 20, 2005; 46(6): 1002 - 1005. [Abstract] [Full Text] [PDF] |
||||
![]() |
G Sianos, A Hoye, F Saia, W van der Giessen, P Lemos, P J de Feyter, P C Levendag, R van Domburg, and P W Serruys Long term outcome after intracoronary {beta} radiation therapy Heart, July 1, 2005; 91(7): 942 - 947. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. T.L. Ong, E. P. McFadden, E. Regar, P. P.T. de Jaegere, R. T. van Domburg, and P. W. Serruys Late Angiographic Stent Thrombosis (LAST) Events With Drug-Eluting Stents J. Am. Coll. Cardiol., June 21, 2005; 45(12): 2088 - 2092. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. K. Prasad, K. R. Resmi, L. K. Krishnan, and R. Vaishnav Survival of Endothelial Cells in vitro on Paclitaxel-loaded Coronary Stents J Biomater Appl, April 1, 2005; 19(4): 271 - 286. [Abstract] [PDF] |
||||
![]() |
J. Fajadet, M.-C. Morice, C. Bode, P. Barragan, P. W. Serruys, W. Wijns, C. R. Constantini, J.-L. Guermonprez, H. Eltchaninoff, D. Blanchard, et al. Maintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Coronary Stents: Three-Year Results of the RAVEL Trial Circulation, March 1, 2005; 111(8): 1040 - 1044. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tanabe, P. W. Serruys, M. Degertekin, E. Grube, G. Guagliumi, W. Urbaszek, J. Bonnier, J.-M. Lablanche, T. Siminiak, J. Nordrehaug, et al. Incomplete Stent Apposition After Implantation of Paclitaxel-Eluting Stents or Bare Metal Stents: Insights From the Randomized TAXUS II Trial Circulation, February 22, 2005; 111(7): 900 - 905. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sabate, G. Pimentel, C. Prieto, J. Corral, C. Banuelos, D. J. Angiolillo, F. Alfonso, R. Hernandez-Antolin, J. Escaned, P. Fantidis, et al. Intracoronary brachytherapy after stenting de novo lesions in diabetic patients: Results of a randomized intravascular ultrasound study J. Am. Coll. Cardiol., August 4, 2004; 44(3): 520 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. W. Serruys, W. Wijns, G. Sianos, I. de Scheerder, P. A. van den Heuvel, W. Rutsch, H. D. Glogar, C. Macaya, P. H. Materne, S. Veldhof, et al. Direct stenting versus direct stenting followed by centered beta-radiation with intravascular ultrasound-guided dosimetry and long-term anti-platelet treatment: Results of a randomized trial: Beta-radiation Investigation with Direct stenting and Galileo in Europe (BRIDGE) J. Am. Coll. Cardiol., August 4, 2004; 44(3): 528 - 537. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. W Radke, S. Kobella, A. Kaiser, A. Franke, D. Schubert, E. Grube, P. Hanrath, and R. Hoffmann Treatment of in-stent restenosis using a paclitaxel-eluting stent: acute results and long-term follow-up of a matched-pair comparison with intracoronary {beta}-radiation therapy Eur. Heart J., June 1, 2004; 25(11): 920 - 925. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Krueger, M. Zaehringer, M. Bendel, H. Stuetzer, D. Strohe, M. Nolte, D. Wittig, R.-P. Mueller, and K. Lackner De Novo Femoropopliteal Stenoses: Endovascular Gamma Irradiation Following Angioplasty--Angiographic and Clinical Follow-up in a Prospective Randomized Controlled Trial Radiology, May 1, 2004; 231(2): 546 - 554. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Jaster, V Fuster, P Rosenthal, M Pauschinger, Q-V Tran, D Janssen, W Hinkelbein, P Schwimmbeck, H-P Schultheiss, and U Rauch Catheter based intracoronary brachytherapy leads to increased platelet activation Heart, February 1, 2004; 90(2): 160 - 164. [Abstract] [Full Text] [PDF] |
||||
![]() |
V Bhatia, R Bhatia, and M Dhindsa Drug-eluting stents: new era and new concerns Postgrad. Med. J., January 1, 2004; 80(939): 13 - 18. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. A. Meyer, B. Nowak, K. Schuermann, A. Buecker, F. Moltzahn, A. Kulisch, N. Heussen, T. Gorgen, U. Bull, and R. W. Gunther Inhibition of Neointimal Proliferation with 188Re-labeled Self-Expanding Nitinol Stent in a Sheep Model Radiology, December 1, 2003; 229(3): 847 - 854. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Scheller, U. Speck, A. Schmitt, M. Bohm, and G. Nickenig Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1415 - 1420. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Farb, A. P. Burke, F. D. Kolodgie, and R. Virmani Pathological Mechanisms of Fatal Late Coronary Stent Thrombosis in Humans Circulation, October 7, 2003; 108(14): 1701 - 1706. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-L. Hang, M. Fu, B.-T. Hsieh, S. W. Leung, C.-J. Wu, H.-K. Yip, and G. Ting Intracoronary {beta}-Irradiation With Liquid Rhenium-188: Results of the Taiwan Radiation in Prevention of Post-Pure Balloon Angioplasty Restenosis Study Chest, October 1, 2003; 124(4): 1284 - 1293. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Sousa, P. W. Serruys, and M. A. Costa New Frontiers in Cardiology: Drug-Eluting Stents: Part II Circulation, May 13, 2003; 107(18): 2383 - 2389. [Full Text] [PDF] |
||||
![]() |
E. Cheneau, M. C. John, J. Fournadjiev, R. C. Chan, H.-S. Kim, L. Leborgne, R. Pakala, H. Yazdi, A. E. Ajani, R. Virmani, et al. Time Course of Stent Endothelialization After Intravascular Radiation Therapy in Rabbit Iliac Arteries Circulation, April 29, 2003; 107(16): 2153 - 2158. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Finkelstein, D. McClean, S. Kar, K. Takizawa, K. Varghese, N. Baek, K. Park, M. C. Fishbein, R. Makkar, F. Litvack, et al. Local Drug Delivery via a Coronary Stent With Programmable Release Pharmacokinetics Circulation, February 11, 2003; 107(5): 777 - 784. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bonvini, I. Baumgartner, D. D. Do, M. Alerci, J.-M. Segatto, P. Tutta, K. Jager, M. Aschwanden, E. Schneider, B. Amann-Vesti, et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries J. Am. Coll. Cardiol., February 5, 2003; 41(3): 409 - 412. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tanabe, P. W. Serruys, E. Grube, P. C. Smits, G. Selbach, W. J. van der Giessen, M. Staberock, P. de Feyter, R. Muller, E. Regar, et al. TAXUS III Trial: In-Stent Restenosis Treated With Stent-Based Delivery of Paclitaxel Incorporated in a Slow-Release Polymer Formulation Circulation, February 4, 2003; 107(4): 559 - 564. [Abstract] [Full Text] [PDF] |
||||
![]() |
R Virmani, F D Kolodgie, A Farb, and A Lafont Drug eluting stents: are human and animal studies comparable? Heart, February 1, 2003; 89(2): 133 - 138. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Sousa, M. A. Costa, A. G.M.R. Sousa, A. C. Abizaid, A. C. Seixas, A. S. Abizaid, F. Feres, L. A. Mattos, R. Falotico, J. Jaeger, et al. Two-Year Angiographic and Intravascular Ultrasound Follow-Up After Implantation of Sirolimus-Eluting Stents in Human Coronary Arteries Circulation, January 28, 2003; 107(3): 381 - 383. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Degertekin, E. Regar, K. Tanabe, P. C. Smits, W. J. van der Giessen, S. G. Carlier, P. de Feyter, J. Vos, D. P. Foley, J. M. R. Ligthart, et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis: The first clinical experience J. Am. Coll. Cardiol., January 15, 2003; 41(2): 184 - 189. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Sousa, M. A. Costa, A. Abizaid, A. G.M.R. Sousa, F. Feres, L. A. Mattos, M. Centemero, G. Maldonado, A. S. Abizaid, I. Pinto, et al. Sirolimus-Eluting Stent for the Treatment of In-Stent Restenosis: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study Circulation, January 7, 2003; 107(1): 24 - 27. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Cheneau, R. Waksman, H. Yazdi, R. Chan, J. Fourdnadjiev, C. Berzingi, V. Shah, A. E. Ajani, L. Leborgne, and F. O. Tio How to Fix the Edge Effect of Catheter-Based Radiation Therapy in Stented Arteries Circulation, October 22, 2002; 106(17): 2271 - 2277. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kataoka, E. Grube, Y. Honda, Y. Morino, S.-H. Hur, H. N. Bonneau, A. Colombo, C. Di Mario, G. Guagliumi, K. E. Hauptmann, et al. 7-Hexanoyltaxol-Eluting Stent for Prevention of Neointimal Growth: An Intravascular Ultrasound Analysis From the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE) Circulation, October 1, 2002; 106(14): 1788 - 1793. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Degertekin, P. W. Serruys, D. P. Foley, K. Tanabe, E. Regar, J. Vos, P. C. Smits, W. J. van der Giessen, M. van den Brand, P. de Feyter, et al. Persistent Inhibition of Neointimal Hyperplasia After Sirolimus-Eluting Stent Implantation: Long-Term (Up to 2 Years) Clinical, Angiographic, and Intravascular Ultrasound Follow-Up Circulation, September 24, 2002; 106(13): 1610 - 1613. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Duda, B. Pusich, G. Richter, P. Landwehr, V. L. Oliva, A. Tielbeek, B. Wiesinger, J. B. Hak, H. Tielemans, G. Ziemer, et al. Sirolimus-Eluting Stents for the Treatment of Obstructive Superficial Femoral Artery Disease: Six-Month Results Circulation, September 17, 2002; 106(12): 1505 - 1509. [Abstract] [Full Text] [PDF] |
||||